| Zabdeno (monovalent ebola virus vaccine) / J&J |
NCT02313077: A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants |
|
|
| Completed | 1 | 87 | Europe | MVA-BN-filo, Ad26. ZEBOV, Placebo | Crucell Holland BV | Healthy | 04/15 | 03/16 | | |
NCT02325050: A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants |
|
|
| Completed | 1 | 164 | US | MVA-BN-Filo, Ad26. ZEBOV, Placebo | Janssen Vaccines & Prevention B.V. | Healthy | 07/15 | 05/17 | | |
NCT02376426: A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants |
|
|
| Completed | 1 | 72 | RoW | MVA-BN-Filo, Ad26.ZEBOV, Placebo | Crucell Holland BV | Healthy | 09/15 | 06/16 | | |
NCT02376400: A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants |
|
|
| Completed | 1 | 78 | RoW | MVA-BN-Filo, Ad26.ZEBOV, Placebo | Crucell Holland BV | Healthy | 12/15 | 09/16 | | |
NCT02860650: A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults |
|
|
| Completed | 1 | 72 | US | Ad26.Filo, MVA-BN-Filo, Ad26.ZEBOV, Placebo | Janssen Vaccines & Prevention B.V., National Institute of Allergy and Infectious Diseases (NIAID) | Healthy | 05/17 | 01/18 | | |
NCT02495246: A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV |
|
|
| Completed | 1 | 32 | Europe | ChAd3-EBO-Z, Ad26.ZEBOV | University of Oxford | Ebola Virus Disease | 08/17 | 08/17 | | |
NCT02891980: A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers |
|
|
| Completed | 1 | 65 | US | Ad26 Zaire Ebola Vaccine, MVA Multi-Filo Ebola Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | Ebola Disease, Marburg Disease | 03/19 | 03/19 | | |
